|Bid||47.00 x 100|
|Ask||50.94 x 500|
|Day's Range||47.51 - 50.73|
|52 Week Range||45.42 - 99.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $130 million.
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
The FDA sees promise in speeding the Boulder-based company's drug to a larger range of patients.
Clovis popped midday Friday after the FDA approved another use for its ovarian cancer drug Rubraca — prodding shares of rival Tesaro to topple.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Clovis Oncology Inc’s (NASDAQ:CLVS): Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The US$2.93B market-cap company announcedRead More...
A panel of European Medicines Agency has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity. However, the EMA's Committee for ...
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 29.
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $1.04. Losses, adjusted for non-recurring gains, were $1.27 per share. The results exceeded Wall Street expectations. The ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Clovis Oncology Inc (NASDAQ:CLVS) as an investment opportunity. If youRead More...
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $64 million over the last one-month into ETFs that hold CLVS are among the lowest of the last year and appear to be slowing.
Clovis Oncology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $198 million over the last one-month into ETFs that hold CLVS are among the lowest of the last year and appear to be slowing.